# Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

> **NCT00294762** · PHASE2 · COMPLETED · sponsor: **OSI Pharmaceuticals** · enrollment: 143 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Tarceva
- **DRUG:** carboplatin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00294762
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2012-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294762, "Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00294762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*